<div id="readability-page-1"><p>Debanjana Chatterjee, an analyst from JonesTrading, maintained the Buy rating on AbSci. The associated price target was raised to $11.00.</p><div><p>Debanjana Chatterjee has given his Buy rating due to a combination of factors, including encouraging early data for ABS-201 and a higher probability of success for the lead AGA program. The clean emerging safety profile, supportive pharmacokinetics, and a dosing schedule that may require just a few injections over six months underpin confidence ahead of key proof-of-concept readouts and justify raising the price target to $11.</p><p>  Chatterjee also highlights AbSci’s strategy to broaden its prolactin receptor franchise with ABS-202 in immunology, while advancing ABS-201 into endometriosis and maintaining capital discipline by seeking partners for oncology assets. This focused allocation of resources toward high-return PRLR programs, combined with potential synergies across dermatology and pain indications, supports the view that the company’s pipeline can create substantial long-term shareholder value.</p></div><p>In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.00 price target.</p></div>

ABSI

SBIO

LABU

IBBQ

<p>Analyst Debanjana Chatterjee from JonesTrading has reiterated a Buy rating on AbSci, raising the price target to $11.00 due to promising early data for ABS-201 and a favorable outlook for the AGA program. The company's strategy to expand its prolactin receptor franchise and maintain capital discipline supports long-term shareholder value. H.C. Wainwright also maintains a Buy rating with a $8.00 price target.</p>

Tip Ranks

Absci

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

AbSci Price Target Raised to $11 as Analyst Reiterates Buy on Promising PRLR Pipeline and ABS-201 Data